Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARALL study of veltuzumab and epratuzumab with chemotherapy in recurrent adult B-precursor acute lymphoblastic leukemia
2008-002286-32Phase 2Terminated
- Sponsor
- Queen Mary University of London
- Start
- Jun 2009
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of veltuzumab and epratuzumab in acute lymphoblastic leukemia (ALL) (3 arms), sponsored by Queen Mary University of London. Primary endpoints: Safety and tolerability and Morphological complete remission on Day 29 bone marrow. Started Jun 2009; status: terminated.
02
Drugs
veltuzumabepratuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2008-002286-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002286-32.